Abstract
Alterations in tyrosine kinase expression or functionality have been linked to tumor growth, and detailed analysis of tyrosine kinase pathways has led to the development of novel anticancer drugs based on their inhibition. The aim of the present work was to examine the cytotoxicity and cellular alterations correlated with multidrug resistance mechanisms induced by three tyrosine kinase inhibitors, lapatinib, sorafenib and gefitinib. The study was performed on three breast cancer cell lines (BRC-230, MCF-7 and SkBr3). Drug-induced growth inhibition was detected by Sulforhodamine B analysis. Apoptosis, cytosolic calcium alteration, extrusion pump activity and mitochondrial membrane depolarization were assessed by flow cytometry. Drug efflux-related gene expression was analyzed by RT-PCR and drug target protein expression was evaluated by Western Blot. Lapatinib and gefitinib induced a cytotoxic effect and mitochondrial membrane depolarization in BRC-230 and SkBr3 cells, while sorafenib induced apoptosis and a high and rapid dissipation of mitochondrial potential in all cell lines. Moreover, all three drugs produced a rapid cytosolic calcium mobilization from endoplasmic reticulum stores in the investigated cell lines and a strong decrease in multidrug transporter activity in BRC- 230 and MCF-7 cells. Mitochondrial membrane depolarization and inhibition of multidrug transporter activity induced by tyrosine kinase inhibitors were independent of cytosolic calcium mobilization. These data suggest that the investigated drugs possess mechanisms of action that are independent of drug target expression, opening up further possibilities for the development of new therapeutic strategies.
Keywords: Tyrosine kinase inhibitor, breast cancer, in vitro study, calcium, multidrug resistance, mitochondrial depolarization, ABC transporters
Current Cancer Drug Targets
Title: Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells
Volume: 10 Issue: 4
Author(s): S. Carloni, F. Fabbri, G. Brigliadori, P. Ulivi, R. Silvestrini, D. Amadori and W. Zoli
Affiliation:
Keywords: Tyrosine kinase inhibitor, breast cancer, in vitro study, calcium, multidrug resistance, mitochondrial depolarization, ABC transporters
Abstract: Alterations in tyrosine kinase expression or functionality have been linked to tumor growth, and detailed analysis of tyrosine kinase pathways has led to the development of novel anticancer drugs based on their inhibition. The aim of the present work was to examine the cytotoxicity and cellular alterations correlated with multidrug resistance mechanisms induced by three tyrosine kinase inhibitors, lapatinib, sorafenib and gefitinib. The study was performed on three breast cancer cell lines (BRC-230, MCF-7 and SkBr3). Drug-induced growth inhibition was detected by Sulforhodamine B analysis. Apoptosis, cytosolic calcium alteration, extrusion pump activity and mitochondrial membrane depolarization were assessed by flow cytometry. Drug efflux-related gene expression was analyzed by RT-PCR and drug target protein expression was evaluated by Western Blot. Lapatinib and gefitinib induced a cytotoxic effect and mitochondrial membrane depolarization in BRC-230 and SkBr3 cells, while sorafenib induced apoptosis and a high and rapid dissipation of mitochondrial potential in all cell lines. Moreover, all three drugs produced a rapid cytosolic calcium mobilization from endoplasmic reticulum stores in the investigated cell lines and a strong decrease in multidrug transporter activity in BRC- 230 and MCF-7 cells. Mitochondrial membrane depolarization and inhibition of multidrug transporter activity induced by tyrosine kinase inhibitors were independent of cytosolic calcium mobilization. These data suggest that the investigated drugs possess mechanisms of action that are independent of drug target expression, opening up further possibilities for the development of new therapeutic strategies.
Export Options
About this article
Cite this article as:
Carloni S., Fabbri F., Brigliadori G., Ulivi P., Silvestrini R., Amadori D. and Zoli W., Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells, Current Cancer Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/156800910791208580
DOI https://dx.doi.org/10.2174/156800910791208580 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Antimutagenic, Antiproliferative and Antioxidant Properties of Sea Grape Leaf Extract Fractions (<i>Coccoloba uvifera</i> L.)
Anti-Cancer Agents in Medicinal Chemistry Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress
Current Drug Targets Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Synthesis of Mannich Bases by Two Different Methods and Evaluation of their Acetylcholine Esterase and Carbonic Anhydrase Inhibitory Activities
Letters in Drug Design & Discovery Integrase Interactor 1 in Health and Disease
Current Protein & Peptide Science Effects of Limonoid Cedrelone on MDA-MB-231 Breast Tumor Cells in vitro
Anti-Cancer Agents in Medicinal Chemistry Applications of Molecular Imaging in Drug Discovery and Development Process
Current Pharmaceutical Biotechnology Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma
Medicinal Chemistry Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions
Current Drug Metabolism